Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery

Cell Chem Biol. 2017 Sep 21;24(9):1092-1100. doi: 10.1016/j.chembiol.2017.06.012. Epub 2017 Jul 27.

Abstract

Tumor organoids are 3D cultures of cancer cells that can be derived on an individual patient basis with a high success rate. This creates opportunities to build large biobanks with relevant patient material that can be used to perform drug screens and facilitate drug development. The high take rate will also allow side-by-side comparison to evaluate the translational potential of this model system to the patient. These tumors-in-a-dish can be established for a variety of tumor types including colorectal, pancreas, stomach, prostate, and breast cancers. In this review, we highlight what is currently known about tumor organoid culture, the advantages and challenges of the model system, compare it with other pre-clinical cancer models, and evaluate its value for drug development.

Keywords: PDX; biobank; cell line; drug development; drug screen; patient-derived tumor organoids; patient-derived xenograft; three-dimensional culture; tumor organoids.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • CRISPR-Cas Systems
  • Cell Culture Techniques
  • Cystic Fibrosis / therapy
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Cystic Fibrosis Transmembrane Conductance Regulator / metabolism
  • Drug Discovery*
  • Humans
  • Models, Biological*
  • Neoplasms / drug therapy
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Cystic Fibrosis Transmembrane Conductance Regulator